Pratteln - Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD).

Subject to a positive study outcome, this could allow for a regulatory submission to the US FDA in the fourth quarter of 2021 with the potential to offer an alternative to current standard of care in young boys with DMD.

The 48-week Phase 2b VISION-DMD study (VBP15-004; clinicaltrials.gov: NCT03439670 [1]) is designed as a pivotal trial to demonstrate efficacy and safety of vamorolone administered orally at doses of 2.0 mg/kg/day and 6.0 mg/kg/day versus prednisone 0.75 mg/kg/day and placebo in ambulant boys ages 4 to

(C) 2020 Electronic News Publishing, source ENP Newswire